Drugs in R&D

Acknowledgement to Referees

Novel Strategies for the Treatment of COVID-19

Matthew W. McCarthy

Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study

Maki Umemiya, Yoshihide Inayama, Eiji Nakatani, Kenta Ito, Mitsuru Tsuji, Teruki Yoshida, Sae Yu, Rei Gou, Naoki Horikawa, Hirohiko Tani, Kenzo Kosaka

Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome

Shuangyan Yang, Junfeng Zhang, Dan Chen, Jie Ding, Yanhong Zhang, Lili Song

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation

Ryohei Ono, Kazutaka Nishimura, Hidehisa Takahashi, Yasuhiko Hori, Kenichi Fukushima, Yoshio Kobayashi

Clinical Validation of the Covariates Pharmacokinetic Model for Propofol in an Adult Population

Christopher Hawthorne, Martin Shaw, Ruaraidh Campbell, Nicholas Sutcliffe, Shiona McKelvie, Stefan Schraag

Chinese- and French-Manufactured Immediate-Release Glucophage® Bioequivalence: A Randomized, Open-Label, Crossover Study

Chaoying Hu, Dan Gao, Dandan Li, Dongli Zhou, Lan Zhang

Pharmacokinetics, Bioequivalence and Safety of Cloperastine in Chinese Healthy Subjects Under Fasting and Postprandial Conditions

Hong-Yu Luo, Hui-Zhi Long, Zi-Wei Zhou, Shuo-Guo Xu, Feng-Jiao Li, Yan Cheng, Dan-Dan Wen, Ping Deng, Li-Chen Gao